EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CAR T-Cell Therapy in Hematological Malignancies: Mechanisms, Innovations, and Challenges

Alaa A A Aljabali iD, Mohammad A Obeid, Abdelrahim Alqudah iD, Yassmen Hamzat, Alaa Alqudah iD, Lorca Alzoubi iD, Omar Gammoh iD, Esam Qnais iD, Vijay Mishra iD, Yachana Mishra iD, Taher Hatahet iD, Mohamed El-Tanani

Cancers · 09.10.2026 · 18 (20) · 3254

DOI: 10.3390/cancers18203254 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 09.10.2026. Verfasst von Alaa A A Aljabali und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University, P.O. Box 566, Irbid 21163, Jordan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed or refractory hematological malignancies, producing deep and durable responses in B-cell acute lymphoblastic leukemia, aggressive B-cell non-Hodgkin lymphomas, and multiple myeloma. Nevertheless, antigen escape, limited in vivo persistence, T-cell exhaustion, and toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) limit broader application. This review synthesizes the mechanistic basis and clinical evidence for the currently approved CAR T-cell products and examines engineering strategies designed to overcome these barriers, including “armored” CAR T cells, multitargeted and logic-gated constructs, and modular or universal platforms intended to extend this approach beyond CD19-positive disease. Combination strategies with immune checkpoint inhibitors, radiotherapy, and other immunotherapies are discussed, together with emerging biomarkers of response and toxicity. Continued optimization of CAR design, toxicity management, and manufacturing scalability will be essential for CAR T-cell therapy to become a foundational pillar of precision oncology.

Schlagwörter

Stichwörter der Autor:innen

chimeric antigen receptor (CAR) T-cell therapyhematological malignanciesimmune checkpoint inhibitorsmultiplexed antigen targetingnext-generation immunotherapy

Autor:innen und Institutionen

  • Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University, P.O. Box 566, Irbid 21163, Jordan.
  • College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah P.O. Box 11172, United Arab Emirates.
  • Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University, Zarqa 13133, Jordan.
  • Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Yarmouk University, P.O. Box 566, Irbid 21163, Jordan.
  • Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Yarmouk University, P.O. Box 566, Irbid 21163, Jordan.
  • Department of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa 13133, Jordan.

ORCID-Profile: Alaa A A Aljabali, Abdelrahim Alqudah, Alaa Alqudah, Lorca Alzoubi, Omar Gammoh, Esam Qnais, Vijay Mishra, Yachana Mishra, Taher Hatahet

Zitieren

APA

Aljabali, A. A. A., Obeid, M. A., Alqudah, A., Hamzat, Y., Alqudah, A., Alzoubi, L., Gammoh, O., Qnais, E., Mishra, V., Mishra, Y., Hatahet, T., & El-Tanani, M. (2026). CAR T-Cell Therapy in Hematological Malignancies: Mechanisms, Innovations, and Challenges. Cancers, 18(20), 3254. https://doi.org/10.3390/cancers18203254

Vancouver

Aljabali AAA, Obeid MA, Alqudah A, Hamzat Y, Alqudah A, Alzoubi L, et al. CAR T-Cell Therapy in Hematological Malignancies: Mechanisms, Innovations, and Challenges. Cancers. 2026;18(20):3254. doi:10.3390/cancers18203254

BibTeX
@article{Aljabali2026,
  author = {Aljabali, Alaa A A and Obeid, Mohammad A and Alqudah, Abdelrahim and Hamzat, Yassmen and Alqudah, Alaa and Alzoubi, Lorca and Gammoh, Omar and Qnais, Esam and Mishra, Vijay and Mishra, Yachana and Hatahet, Taher and El-Tanani, Mohamed},
  title = {CAR T-Cell Therapy in Hematological Malignancies: Mechanisms, Innovations, and Challenges},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {20},
  pages = {3254},
  doi = {10.3390/cancers18203254}
}
Kostenlos starten →